Ind-Swift Labs board to meet on May 28 to consider FY26 results
Ind-Swift Laboratories Ltd. will hold a board meeting on May 28, 2026, to approve the standalone and consolidated audited financial results for the quarter and fiscal year ended March 31, 2026.

*this image is generated using AI for illustrative purposes only.
Ind-Swift Laboratories Ltd. has announced that its board of directors will meet on Thursday, May 28, 2026. The primary agenda of the meeting is to consider, approve, and take on record the Standalone and Consolidated Audited Financial Results of the company for the quarter and financial year ended March 31, 2026.
The company has informed the stock exchanges regarding the closure of the trading window for dealing in its securities. This information was previously communicated via a letter dated March 31, 2026.
Meeting Details
| Parameter | Details |
|---|---|
| Event | Board Meeting |
| Date | May 28, 2026 |
| Purpose | Consideration of Audited Financial Results |
| Period | Quarter and Financial Year ended March 31, 2026 |
| Financials | Standalone and Consolidated |
The regulatory notice was dispatched to BSE Limited and the National Stock Exchange of India Limited. The company has also made this information available on its official website under the Investors section.
Ind-Swift Laboratories Ltd. is a pharmaceutical entity with manufacturing facilities located in Punjab and Jammu & Kashmir. The registered office is situated in Chandigarh.
Historical Stock Returns for Ind Swift Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.63% | -2.09% | -8.44% | +31.06% | +83.19% | +58.21% |
How might Ind-Swift Laboratories' FY2026 revenue and profitability compare to the previous fiscal year, given the competitive pressures in the Indian pharmaceutical manufacturing sector?
Will the board meeting on May 28 include any announcements regarding dividend declarations, capital expenditure plans, or expansion of manufacturing facilities in Punjab or Jammu & Kashmir?
How could potential regulatory changes in pharmaceutical export policies affect Ind-Swift Laboratories' consolidated financial performance in FY2027?


































